Bioactive factors for bone tissue engineering.
Orthopaedic surgery is currently in the midst of a transformation from bone grafting and the use of bone graft substitutes to bone tissue engineering. Bioactive bone growth factors likely will play a particularly important role in this emerging field. This article will review the three leading strategies for using bioactive factors for bone tissue engineering: extraction and partial purification of growth factors, recombinant protein synthesis, and gene therapy. Preclinical and early clinical trial results with bone morphogenetic protein-2, bone morphogenetic protein-7 (osteogenic protein-1), and NeOsteo bovine bone protein extract will be reviewed. In addition, the current obstacles to clinical implementation of bone tissue engineering will be reviewed.
Boden
S D
SD
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA 30033, USA.
D000818:Animals; D001709:Biotechnology; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology; D001842:Bone and Bones / Q000166:cytology*; D018929:Cell Culture Techniques; D005818:Genetic Engineering; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007335:Insulin-Like Growth Factor II; D011506:Proteins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology
D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; C035170:IGF2 protein, human; D011506:Proteins; D011994:Recombinant Proteins; D007335:Insulin-Like Growth Factor II